Pharmaceuticals News & Press Release Distribution

Viraleze registered for sale in Covid-ravaged India

MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country. The announcement...

2021-06-11 15:15 14023

Viraleze registered for sale in Covid-ravaged India

MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country. The announcement...

2021-06-11 15:03 2127

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based inOsaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test conducte...

2021-06-11 14:00 2613

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based inOsaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test conducte...

2021-06-11 14:00 3145

Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2021 Congress

SHANGHAI, June 11, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of ...

2021-06-11 13:05 3014

Happiness Biotech Entered Into Electric Vehicle Distribution Agreement With Geely's Subsidiary

NANPING, China, June 10, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, announced today that Taochejun (Fujian) Automobile Distribution Co., Ltd. ("Taoc...

2021-06-10 21:00 12714

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

LONDON and RALEIGH, N.C., and SHANGHAI, June 10, 2021 /PRNewswire/ -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma") and Nuance Pharma Limited ("Nuance Pharma"), today announce that the companies have entered into an agreement granting Nuance Pharma, aShanghai-based specialty pharmaceutical c...

2021-06-10 14:00 2887

Enamine implements CDD Vault to digitalize its integrated medicinal chemistry, ADME-PK and screening services

The company's expansion in the biological assay space aided by the data platform SAN FRANCISCO and KYIV, Ukraine, June 10, 2021 /PRNewswire/ -- Enamine, a leading provider of R&D Services as well asScreening Compounds, Fragments, Building Blocks and specialized libraries for Drug Discovery, annou...

2021-06-10 13:57 2243

WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates

WUXI, China and DAEJEON, South Korea, June 10, 2021 /PRNewswire/ -- WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS,"LCB"), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnershi...

2021-06-10 08:30 5942

Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer

SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment ofCharles S. Ryan, JD, PhD as President and Chief Execut...

2021-06-09 21:00 2040

China Pharma to Launch Highly Purified NMN+PQQ Product

HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale ...

2021-06-09 20:00 10377

European Patent Office upholds Curadev's cyclodextrin patent for new composition of matter

SANDWICH, England, June 9, 2021 /PRNewswire/ -- Sulphobutyl ether β-cyclodextrin (SBE-β-CD) is used as an excipient to improve the solubility and stability of a range of active pharmaceutical ingredients, prominent among which is the antifungal drug, voriconazole. Working with ProfessorSteve Wick...

2021-06-09 19:50 2328

Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer

SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd. incorporated inSingapore on 7th April 2017, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment of Charles S....

2021-06-09 13:38 2275

Cytiva opens experience and learning lab in Singapore

* New lab will support Singapore government's Industry 4.0 agenda to build research, digital, innovation capability and talent development * Part of Cytiva's capacity expansion plan to meet the increasing demands for the biopharmaceuticals industry * Through this lab, Cytiva intends to run 7...

2021-06-08 10:00 2352

Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL

SUZHOU, China, and ROCKVILLE, MD, June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released updated results from the first...

2021-06-08 07:30 5647

Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs

SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today presented in an oral presentation at t...

2021-06-08 07:21 12987

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Ins...

2021-06-07 20:00 7310

RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study

The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464 Opaganib is uniquely positioned as a leading novel, dual-action, investigational COVID-19 oral pill Blinded blended mortality rates encourag...

2021-06-07 19:00 5505

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021

SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...

2021-06-07 10:11 7257

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021

* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...

2021-06-07 10:10 6730